Literature DB >> 20962028

Hypoxia and hypoxia-inducible factors: master regulators of metastasis.

Xin Lu1, Yibin Kang.   

Abstract

Hypoxia is a common condition found in a wide range of solid tumors and is often associated with poor prognosis. Hypoxia increases tumor glycolysis, angiogenesis, and other survival responses, as well as invasion and metastasis by activating relevant gene expressions through hypoxia-inducible factors (HIF). HIF-1α and HIF-2α undergo oxygen-dependent regulation, and their overexpression is frequently associated with metastasis and poor clinical outcomes. Recent studies show that each step of the metastasis process, from the initial epithelial-mesenchymal transition to the ultimate organotropic colonization, can potentially be regulated by hypoxia, suggesting a master regulator role of hypoxia and HIFs in metastasis. Furthermore, modulation of cancer stem cell self-renewal by HIFs may also contribute to the hypoxia-regulated metastasis program. The hypoxia-induced metastatic phenotype may be one of the reasons for the modest efficacy of antiangiogenic therapies and may well explain the recent provocative findings that antiangiogenic therapy increased metastasis in preclinical models. Multiple approaches to targeting hypoxia and HIFs, including HIF inhibitors, hypoxia-activated bioreductive prodrugs, and gene therapies may become effective treatments to prevent or reduce metastasis. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962028      PMCID: PMC3005023          DOI: 10.1158/1078-0432.CCR-10-1360

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  71 in total

1.  Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.

Authors:  Manali S Bendre; Aaron G Margulies; Brandon Walser; Nisreen S Akel; Sudeepa Bhattacharrya; Robert A Skinner; Frances Swain; Vishnu Ramani; Khalid S Mohammad; Lisa L Wessner; Alfredo Martinez; Theresa A Guise; John M Chirgwin; Dana Gaddy; Larry J Suva
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

2.  Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer.

Authors:  Yonghua Zhu; David T Denhardt; Hongbin Cao; Patrick D Sutphin; Albert C Koong; Amato J Giaccia; Quynh-Thu Le
Journal:  Oncogene       Date:  2005-09-29       Impact factor: 9.867

3.  Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.

Authors:  Dongfang Wang; Hangjun Ruan; Lily Hu; Kathleen R Lamborn; Eileen L Kong; Alnawaz Rehemtulla; Dennis F Deen
Journal:  Cancer Gene Ther       Date:  2005-03       Impact factor: 5.987

4.  Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy.

Authors:  N Ingram; C D Porter
Journal:  Gene Ther       Date:  2005-07       Impact factor: 5.250

5.  Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model.

Authors:  Tomoko Ozawa; Jethro L Hu; Lily J Hu; Eileen L Kong; Andrew W Bollen; Kathleen R Lamborn; Dennis F Deen
Journal:  Cancer Gene Ther       Date:  2005-05       Impact factor: 5.987

Review 6.  The role of autocrine motility factor in tumor and tumor microenvironment.

Authors:  Tatsuyoshi Funasaka; Avraham Raz
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

7.  Direct regulation of TWIST by HIF-1alpha promotes metastasis.

Authors:  Muh-Hwa Yang; Min-Zu Wu; Shih-Hwa Chiou; Po-Min Chen; Shyue-Yih Chang; Chung-Ji Liu; Shu-Chun Teng; Kou-Juey Wu
Journal:  Nat Cell Biol       Date:  2008-02-24       Impact factor: 28.824

8.  Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.

Authors:  Balaji Krishnamachary; David Zagzag; Hideko Nagasawa; Karin Rainey; Hiroaki Okuyama; Jin H Baek; Gregg L Semenza
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

9.  TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4.

Authors:  David Padua; Xiang H-F Zhang; Qiongqing Wang; Cristina Nadal; William L Gerald; Roger R Gomis; Joan Massagué
Journal:  Cell       Date:  2008-04-04       Impact factor: 41.582

10.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

Authors:  Rosandra N Kaplan; Rebecca D Riba; Stergios Zacharoulis; Anna H Bramley; Loïc Vincent; Carla Costa; Daniel D MacDonald; David K Jin; Koji Shido; Scott A Kerns; Zhenping Zhu; Daniel Hicklin; Yan Wu; Jeffrey L Port; Nasser Altorki; Elisa R Port; Davide Ruggero; Sergey V Shmelkov; Kristian K Jensen; Shahin Rafii; David Lyden
Journal:  Nature       Date:  2005-12-08       Impact factor: 49.962

View more
  280 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

Review 2.  Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.

Authors:  L V Klotz; M E Eichhorn; B Schwarz; H Seeliger; M K Angele; K-W Jauch; Christiane J Bruns
Journal:  Langenbecks Arch Surg       Date:  2012-03-14       Impact factor: 3.445

3.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Authors:  Sarah J Conley; Elizabeth Gheordunescu; Pramod Kakarala; Bryan Newman; Hasan Korkaya; Amber N Heath; Shawn G Clouthier; Max S Wicha
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 4.  Oxygen levels and the regulation of cell adhesion in the nervous system: a control point for morphogenesis in development, disease and evolution?

Authors:  Kathryn L Crossin
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

5.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

6.  A Pilot Study of Texture Analysis of Primary Tumor [18F]FDG Uptake to Predict Recurrence in Surgically Treated Patients with Non-small Cell Lung Cancer.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Tetsuya Shinaji; Masaya Aoki; Atsushi Tani; Yoshiaki Nakabeppu; Masayuki Nakajo; Masami Sato; Takashi Yoshiura
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

7.  Modulating effects of preconditioning exercise in the expression of ET-1 and BNP via HIF-1α in ischemically injured brain.

Authors:  Huijie Wang; Feng Niu; Wei Fan; Jimin Shi; Jihong Zhang; Bing Li
Journal:  Metab Brain Dis       Date:  2019-06-20       Impact factor: 3.584

8.  Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device.

Authors:  Bee Luan Khoo; Gianluca Grenci; Ying Bena Lim; Soo Chin Lee; Jongyoon Han; Chwee Teck Lim
Journal:  Nat Protoc       Date:  2017-12-07       Impact factor: 13.491

9.  Identification of candidate genes that may contribute to the metastasis of prostate cancer by bioinformatics analysis.

Authors:  Lingyun Liu; Kaimin Guo; Zuowen Liang; Fubiao Li; Hongliang Wang
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

10.  Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia.

Authors:  Y Xi; Y Wei; B Sennino; A Ulsamer; I Kwan; A N Brumwell; K Tan; M K Aghi; D M McDonald; D M Jablons; H A Chapman
Journal:  Oncogene       Date:  2012-12-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.